Citadel Advisors
BCDA icon

Citadel Advisors’s BioCardia BCDA Stock Holding History

Citadel Advisors’s Portfolio BCDA Stock Details BCDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,147
Closed -$7K – 14244
2024
Q1 		$7K Sell
1,147
-1,526
-57% -$10.9K ﹤0.01% 13638
2023
Q4 		$26.6K Sell
2,673
-54
-2% -$438 ﹤0.01% 12371
2023
Q3 		$17.5K Buy
2,727
+994
+57% +$16.7K ﹤0.01% 12725
2023
Q2 		$69.4K Sell
1,733
-3,560
-67% -$110K ﹤0.01% 11404
2023
Q1 		$156K Buy
5,293
+1,473
+39% +$48.9K ﹤0.01% 10580
2022
Q4 		$120K Sell
3,820
-107
-3% -$3.04K ﹤0.01% 10968
2022
Q3 		$114K Buy
3,927
+1,187
+43% +$30.7K ﹤0.01% 10976
2022
Q2 		$61K Buy
2,740
+1,793
+189% +$42.9K ﹤0.01% 11803
2022
Q1 		$29K Sell
947
-4,166
-81% -$124K ﹤0.01% 13118
2021
Q4 		$149K Buy
5,113
+3,193
+166% +$117K ﹤0.01% 12263
2021
Q3 		$90K Buy
1,920
+1,100
+134% +$53.9K ﹤0.01% 12974
2021
Q2 		$49K Buy
+820
New +$49.8K ﹤0.01% 13343

Other funds holding BCDA

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PP
Pingora Partners Wilson, Wyoming $171M AUM 60.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Citadel Advisors's BCDA Position: Q2 2026 in Review

Citadel Advisors reduced its BioCardia (BCDA) stake by 64% in Q2 2026, selling an estimated $42.6K and leaving 22,956 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #13316.

Citadel Advisors first reported a position in BCDA in Q4 2020 and has held it in 14 quarters since. The position peaked at $125K in Q2 2021. 21 funds tracked by Wall St. Rank hold BCDA as of Q2 2026.

  • Citadel Advisors held 22,956 shares of BioCardia worth $28.5K as of Q2 2026.
  • Citadel Advisors sold 40,428 BioCardia shares in Q2 2026, an estimated $42.6K.
  • BioCardia made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13316 holding.
  • Citadel Advisors first reported a position in BioCardia in Q4 2020 and has held it in 14 quarters since.
  • Citadel Advisors's BioCardia position peaked at $125K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held BioCardia as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.